systemic lupus erythematosus

Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus

By MedXY 09/04/2026

Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.

Dermatology Hematology-Oncology news

Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case-Cohort Analysis of Clonal Inflammation

By MedXY 03/04/2026

MDS and CMML can present with lupuslike manifestations that represent a distinct entity of clonal inflammation rather than idiopathic autoimmunity. This study highlights the need for clone-directed therapies over standard lupus treatments.

$Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach$

Hematology-Oncology news Rheumatology

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY 11/12/2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and plasma‑cell clones.

Internal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

$Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis$

Allergy & Immunology Clinical Updates Rheumatology Specialties

Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis

By MedXY 09/04/2025

A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicated by lupus nephritis.

Allergy & Immunology Medical News news Rheumatology Specialties

Fine Particulate Matter Exposure Significantly Increases SLE Risk

By MedXY 08/04/2025

A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.